Finance

Beta
Lists
C17:FRA
Corvus Pharmaceuticals Inc
€9.94
+2.05%
(+0.20) 1D
Jun 3, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for C17...
Open
€9.65
High
€9.94
Low
€9.65
Mkt. cap
975.45M
Avg. vol.
2.00
Volume
0.00
52-wk high
€21.70
52-wk low
€3.04
No. of employees
37
Open
€9.65
High
€9.94
Low
€9.65
Mkt. cap
975.45M
Avg. vol.
2.00
Volume
0.00
52-wk high
€21.70
52-wk low
€3.04
No. of employees
37
News stories
From sources across the web
About Corvus Pharmaceuticals Inc
CEO-
Employees37
Founded2014
HeadquartersBurlingame, California, United States
SectorBiotechnology
Websitecorvuspharma.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
7.87M
8.45M
9.94M
11.18M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.39M
2.12M
2.28M
3.70M
Operating expense
10.26M
10.57M
12.22M
14.88M
Total operating expenses
10.26M
10.57M
12.22M
14.88M
Operating income
-10.26M
-10.57M
-12.22M
-14.88M
Other non operating income
2.01M
-
-
-
EBT including unusual items
-8.00M
-10.16M
-12.32M
-13.69M
EBT excluding unusual items
-8.00M
-10.16M
-12.32M
-13.69M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-8.00M
-10.16M
-12.32M
-13.69M
Net profit margin
-
-
-
-
Earnings per share
-0.13
-0.12
-0.15
-0.15
Interest and investment income
639.00K
738.00K
603.00K
1.78M
Interest expense
-
-
-
-
Net interest expenses
639.00K
738.00K
603.00K
1.78M
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.23M
-10.54M
-12.19M
-14.85M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer